The development of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL, such as imatinib mesylate (IM), has revolutionized the treatment of CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.